Traveller spent two months in a coma and died TWICE after developing leukaemia on her gap year
Freya Clarke, 26, from East Grinstead, Sussex, quit her sales and marketing job after becoming 'bored' with London life. Within days of arriving in Sydney, she was diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2018 Category: Consumer Health News Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Stress hormone linked to leukaemia progression
Cortisol is a key activator in a pathway that enables acute myeloid leukaemia cells to evade the immune system, according to a study published inCellular& Molecular Immunology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 15, 2018 Category: Endocrinology Source Type: news

Stress hormone is key factor in failure of immune system to prevent leukemia
(University of Kent) The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 14, 2018 Category: Cancer & Oncology Source Type: news

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring
While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - August 14, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Medical News Today: What is the outlook for chronic lymphocytic leukemia?
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Although doctors can very rarely cure CLL, survival rates for this cancer are typically good. A person ’s life expectancy for CLL depends on how far the cancer has progressed and when they receive treatment. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

Medical News Today: Leukemia: Do genes influence how people respond to therapy?
Some people with acute myeloid leukemia are more responsive to chemotherapy than others. Why is this, and how can this knowledge lead to better treatments? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

Researchers uncover a major new vulnerability of childhood leukemia
(Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)) A team of researchers from IOCB Prague, KU Leuven, and Baylor College of Medicine has recently uncovered a major new vulnerability of mixed lineage leukemia. Their findings, published in a recent issue of the journal PNAS, reports that a protein called LEDGF/p75 is regulated by phosphorylation, a molecular modification that changes the electrical charge of the LEDGF/p75 protein. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 13, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: Poison or cure? Arsenic can help treat cancer, study finds
A new study shows how an arsenic oxide, in combination with an existing drug, can cure leukemia, and it may be able to also treat other types of cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Thousands could benefit from leukaemia drug banned for patients given all-clear after NHS U-turn  
NHS England previously limited Ibrutinib so patients who had been in remission for more than three years missed out. The once-daily pill works by inhibiting the growth of cancerous cells. (Source: the Mail online | Health)
Source: the Mail online | Health - August 10, 2018 Category: Consumer Health News Source Type: news

BBC's Sue Marchant fulfils cancer patient's wish
A teenage girl, who has incurable leukaemia, had a wish to hang out with a DJ. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 9, 2018 Category: Consumer Health News Source Type: news

Arsenic, existing drug combo could treat cancer, study finds
Arsenic in combination with an existing leukemia drug successfully targeted the disease in mice, and offers hope of new treatment for diverse types of cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 9, 2018 Category: Consumer Health News Source Type: news

Arsenic in combination with an existing drug could combat cancer
(Beth Israel Deaconess Medical Center) Investigators have discovered that arsenic in combination with an existing leukemia drug work together to target a master cancer regulator. The team, led by researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC), is hopeful that the discovery could lead to new treatment strategies for diverse types of cancer. Their findings were published today online in Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2018 Category: Cancer & Oncology Source Type: news

Melanoma linked with CLL, close monitoring recommended
(University of Rochester Medical Center) While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news

Discovery could lead to better treatment for leukemia
(University of Illinois at Chicago) Scientists from the University of Illinois at Chicago report on how a certain mutation helps improve sensitivity to chemotherapy in patients in the journal JCI Insight. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2018 Category: Cancer & Oncology Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Researchers Find New Mesothelioma Genes in Family Study
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - August 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Stowers breakthrough could make stem cells available where bone marrow matches aren't
A new discovery by the Stowers Institute of Medical Research could make more resources available to patients who might not have a bone marrow transplant match available. In cases where a patient with leukemia or a blood disorder doesn't have a bone marrow match, blood-forming adult stem cells from the umbilical cord can be transplanted. Just 30 percent of patients have a donor match in their family. However, adult patients need about two cords' worth for treatmen t, meaning there aren't enough available… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 6, 2018 Category: Biotechnology Authors: Elise Reuter Source Type: news

Stowers breakthrough could make stem cells available where bone marrow matches aren't
A new discovery by the Stowers Institute of Medical Research could make more resources available to patients who might not have a bone marrow transplant match available. In cases where a patient with leukemia or a blood disorder doesn't have a bone marrow match, blood-forming adult stem cells from the umbilical cord can be transplanted. Just 30 percent of patients have a donor match in their family. However, adult patients need about two cords' worth for treatmen t, meaning there aren't enough available… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 6, 2018 Category: American Health Authors: Elise Reuter Source Type: news

Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Low-Dose Radiation Exposure Early in Life Tied to Higher Leukemia Risk Low-Dose Radiation Exposure Early in Life Tied to Higher Leukemia Risk
Cumulative exposure to low levels of ionizing radiation is associated with an increased risk of developing leukemia, according to a new analysis.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

'Very promising' drug may cure pancreatic cancer
Researchers from Barts Cancer Institute found that the treatment cures mice with the disease by using the rodents' immune cells to attack tumours, with similar medication being effective for leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2018 Category: Consumer Health News Source Type: news

Chinese leukemia patient livestreams to pay for treatment
(Source: ABC News: Health)
Source: ABC News: Health - July 31, 2018 Category: Consumer Health News Tags: Health Source Type: news

Supplementing leukemia therapy
Increasing the amount of dietary histidine enhances the sensitivity of leukemia xenografts in mice to methotrexate. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - July 31, 2018 Category: Science Authors: Foley, J. F. Tags: STKE Editors ' Choice Source Type: news

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
(University of Colorado Anschutz Medical Campus) Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2018 Category: Biology Source Type: news

Solution to medical mystery may help some children avoid bone marrow transplantation
(St. Jude Children's Research Hospital) Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder. The answer may allow some children to avoid the risk and expense of bone marrow transplantation, a common treatment for leukemia and bone marrow disorders. Investigators at St. Jude Children's Research Hospital and UCSF, led the study, which appears today in the scientific journal JCI Insight.The disorder is myelodysplasia and leukemia syndrome with monosomy 7. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 26, 2018 Category: Biology Source Type: news

Benefit to Targeting Btk in Selected Patients With AML?
A preclinical study of ibrutinib provides compelling evidence that myeloid leukemias with mutatedG-CSFR have abnormal activation of Btk. (Source: CancerNetwork)
Source: CancerNetwork - July 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

FDA Approves Tibsovo for Acute Myeloid Leukemia
MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. Tibsovo's effectiveness was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2018 Category: Pharmaceuticals Source Type: news

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.
CARY, N.C. (July 23, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1 inhibitor approved by the U.S. Food a... (Source: McKesson News)
Source: McKesson News - July 23, 2018 Category: Information Technology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
Title: Tibsovo Approved for Acute Myeloid LeukemiaCategory: Health NewsCreated: 7/21/2018 12:00:00 AMLast Editorial Review: 7/23/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 23, 2018 Category: Cancer & Oncology Source Type: news

'Hijacked' cell response to stress reveals promising drug targets for blood cancer
(NYU Langone Health / NYU School of Medicine) A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2018 Category: Cancer & Oncology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 -- The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML
The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 20, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
FRIDAY, July 20, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. " The use of Tibsovo is associated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2018 Category: General Medicine Source Type: news

FDA OKs Targeted Agent for Acute Myeloid Leukemia
(MedPage Today) -- Approved therapies now available for IDH1- and IDH2-mutant disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 20, 2018 Category: American Health Source Type: news

Agios Pharmaceuticals leukemia drug gets U.S. approval
Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation. (Source: Reuters: Health)
Source: Reuters: Health - July 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 20, 2018 Category: American Health Source Type: news

FDA approves Agios Pharmaceuticals leukemia drug
Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator. (Source: Reuters: Health)
Source: Reuters: Health - July 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML. (Source: World Pharma News)
Source: World Pharma News - July 20, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Women With Diabetes Face Greater Cancer Risk Than Men Women With Diabetes Face Greater Cancer Risk Than Men
Women with diabetes are more likely to develop cancer than men with the condition, with the risk of kidney, oral and stomach cancer, and leukaemia, particularly increased, suggests a review.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Diabetes raises risk of cancer, with women at even greater likelihood, a major new study has found
(George Institute for Global Health) A global review involving almost 20 million people has shown that having diabetes significantly raises the risk of developing cancer, and for women the risk is even higher.Researchers from The George Institute for Global Health also found diabetes (type 1 and type 2) conferred an additional risk for women, compared to men, for leukaemia and cancers of the stomach, mouth and kidney, but less risk for liver cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2018 Category: Cancer & Oncology Source Type: news

An alternative treatment for leukemia
(Source: ScienceNOW)
Source: ScienceNOW - July 19, 2018 Category: Science Authors: Ferrarelli, L. K. Tags: twis Source Type: news

Cancer drug movie strikes nerve in China, becomes box-office hit
A low-budget Chinese movie about a leukemia patient who turns to smuggling cheaper  cancer drugs from India has struck a chord with Internet users and even the country's leaders, spotlighting national anxieties about unaffordable hospital care. (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Strengthen advice on allergenic foods for babies, government urged
Hen ’s egg and peanuts can be safely introduced from age of six months Related items fromOnMedica UK lagging behind peers on child health Breastfeeding could cut children ’s leukaemia risk Scotland reveals target of halving child obesity by 2030 UK child health near bottom in Europe Preschool tooth extractions rise by a quarter (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 18, 2018 Category: UK Health Source Type: news

Officials investigating spike in cancers on Long Island  
New York health officials are investigating after significant rates of leukemia, bladder, lung and thyroid cancers were found in three Long Island counties - 16 percent of all cases in New York state. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2018 Category: Consumer Health News Source Type: news